Research
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Anke Huss, Pippa Scott, Andreas E. Stuck, Caroline Trotter and Matthias Egger
CMAJ January 06, 2009 180 (1) 48-58; DOI: https://doi.org/10.1503/cmaj.080734
Anke Huss PhD
Pippa Scott MSc
Andreas E. Stuck MD
Caroline Trotter PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Anke Huss, Pippa Scott, Andreas E. Stuck, Caroline Trotter, Matthias Egger
CMAJ Jan 2009, 180 (1) 48-58; DOI: 10.1503/cmaj.080734
Jump to section
Related Articles
Cited By...
- Pneumococcal Vaccination Strategies Among HIV-infected Adult Patients: A Review of the Literature
- Accuracy of High-Throughput Nanofluidic PCR-Based Pneumococcal Serotyping and Quantification Assays Using Sputum Samples for Diagnosing Vaccine Serotype Pneumococcal Pneumonia: Analyses by Composite Diagnostic Standards and Bayesian Latent Class Models
- Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
- Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases
- Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study
- Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
- Open-Label Trial of Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Adults >=50 Years of Age in Mexico
- Prospective Cohort Study on the Effectiveness of Influenza and Pneumococcal Vaccines in Preventing Pneumonia Development and Hospitalization
- Randomized Controlled Study of the Safety and Immunogenicity of Pneumococcal Vaccine Formulations Containing PhtD and Detoxified Pneumolysin with Alum or Adjuvant System AS02V in Elderly Adults
- Risk factors for community-acquired pneumonia in adults in Europe: a literature review
- Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment
- Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies
- Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
- Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients
- What's new in respiratory infections and tuberculosis 2008-2010
- Infection with Conditionally Virulent Streptococcus pneumoniae {Delta}pab Strains Induces Antibody to Conserved Protein Antigens but Does Not Protect against Systemic Infection with Heterologous Strains
- Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis
- Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study
- EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
- Immune Responses to Recombinant Pneumococcal PsaA Antigen Delivered by a Live Attenuated Salmonella Vaccine
- Pneumococcal polysaccharide vaccine in high risk adults
- Temporal Analysis of Invasive Pneumococcal Clones from Scotland Illustrates Fluctuations in Diversity of Serotype and Genotype in the Absence of Pneumococcal Conjugate Vaccine
- Identification of new risk factors for pneumonia: population-based case-control study
- T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces
- Efficacy of pneumococcal polysaccharide vaccine
- Efficacy of pneumococcal polysaccharide vaccine
- Pneumococcal Polysaccharide Vaccine: Efficacy Remains Controversial
- The controversy over the efficacy of pneumococcal vaccine